Bladder Urothelial Carcinoma — Trials

Bladder Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

138 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 60
Recruiting: 23
Ph III recruiting: 3
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 47.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07725796	A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC	not yet recruiting	Phase 1	30	UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.INDUSTRY	1	Jul 24, 2026	clinicaltrials
NCT07064863	A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME)	not yet recruiting	Phase 1 / Phase 2	31	Queen's UniversityOTHER	1